Investigation for efficacy and safety of high dose chemotherapy (MEAM) supported with auto-PBSCT for malignant lymphoma (THF 13)

Investigation for efficacy and safety of high dose chemotherapy (MEAM) supported with auto-PBSCT for malignant lymphoma (THF 13) - MEAM-auto-PBSCT-ML (THF 13)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002743

Enrollment

Registered

2009-11-10

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma

Interventions

Investigation for efficacy and safety of high dose chemotherapy (MEAM) supported with auto-PBSCT for malignant lymphoma.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. pathohistological diagnosed for malignant lymphoma 2. indication for high dose chemotherapy (MEAM) with auto-PBSCT 3. CD34+cell>2x106/kg are available 4 patients approved by written informed consent 5 age:20-65 6 performance status of 0-2 7 no major organ dysfunction 8 no cardiac abnormality to need treatment 9 ejection fraction >50%

Exclusion criteria

Exclusion criteria: 1 severe bacterial infection 2 positive test for HIV antibody 3 positive test for HBs antigen 4 positive test for HCV antibody 5 angina pectoris, myocardial infarction, treatment required arrhythmia 6 interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events, incidnece of therapy related mortality	—

Countries

Japan

Contacts

Public ContactYoshihiro Kameoka

Akita University School of Medicine Dept. of hematology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026